



NDA 50-590/S-052
NDA 50-658/S-018

GlaxoSmithKline
Attention: Deneen Stewart, Ph.D.
Assistant Director, U.S. Regulatory Affairs
One Franklin Plaza
P.O. Box 7929
Philadelphia, Pennsylvania 19101-7929

Dear Dr. Stewart:

Please refer to your supplemental new drug applications dated January 21, 2004 (S-052) and January 19, 2004 (S-018), received January 22, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Timentin[®] (sterile ticarcillin disodium/clavulanate potassium) Injection (NDA 50-590), and Timentin[®] (sterile ticarcillin disodium/clavulanate potassium) Galaxy[™] (PL2040) Plastic Container (NDA 50-658). These applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated October 11, 2004.

These supplemental new drug applications provide for revised labeling to comply with the Final Rule entitled "Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human Use" (68FR 6062, February 6, 2003).

We have completed our review of these applications, as amended and they are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (text for the package insert dated October 11, 2004), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit the FPL electronically according to the Guidance for Industry titled "Providing Regulatory Submissions in Electronic Format – NDA". Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-590/S-052 and NDA 50-658/S-018". Approval of these submissions by FDA is not required before the labeling is used.

NDA 50-590/S-052

NDA 50-658/S-018

Page 2

If you issue a letter communicating important information about these drug products (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to these NDAs and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, M.D., Regulatory Project Manager, at (301) 827-2125.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth
11/19/04 11:30:33 AM